Scan here or visit
BRILINTATouchPoints.com
DRUG INTERACTIONS
• Avoid use with strong CYP3A inhibitors and strong CYP3A
inducers. BRILINTA is metabolized by CYP3A4/5. Strong
inhibitors substantially increase ticagrelor exposure and
so increase the risk of adverse events. Strong inducers
substantially reduce ticagrelor exposure and so decrease
the efficacy of ticagrelor
• Patients receiving more than 40 mg per day